SY20-3 Development of treatment for HER2 or EGFR exon 20 insertion mutation-driven NSCLC

Abstract

Mutations in human epidermal growth factor receptor 2 (ERBB2; HER2) are the major reason for the development of approximately 3% of non-squamous non-small cell lung cancer (NSCLC) cases, of which about half of the cases are due to insertions in exon 20. Patients with these mutations generally tend to be younger, female, and have a poor prognosis. To date, various drugs have been tested as targeted therapies for HER2-mutated NSCLC, but no drugs have been approved. Our phase 2 trial of trastuzumab-emtansine (T-DM1), an anti-HER2 antibody-drug conjugate, initially showed some response in HER2-mutated lung cancer.